Furthermore, a bsAb with specificities for NKG2D and SLAM family member 7 (SLAMF7; CS-1; CD319) was shown to exert therapeutic effects in preclinical models of MM (37). This evidence concerns the gene SLAMF7 and Miyoshi myopathy.